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Rabphilin 3A retains NMDA receptors at synaptic
sites through interaction with GluN2A/PSD-95
complex
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NMDA receptor (NMDAR) composition and synaptic retention represent pivotal features in
the physiology and pathology of excitatory synapses. Here, we identify Rabphilin 3A (Rph3A)
as a new GluN2A subunit-binding partner. Rph3A is known as a synaptic vesicle-associated
protein involved in the regulation of exo- and endocytosis processes at presynaptic sites. We
find that Rph3A is enriched at dendritic spines. Protein–protein interaction assays reveals that
Rph3A N-terminal domain interacts with GluN2A(1349–1389) as well as with PSD-95(PDZ3)
domains, creating a ternary complex. Rph3A silencing in neurons reduces the surface
localization of synaptic GluN2A and NMDAR currents. Moreover, perturbing GluN2A/Rph3A
interaction with interfering peptides in organotypic slices or in vivo induces a decrease
of the amplitude of NMDAR-mediated currents and GluN2A density at dendritic spines.
In conclusion, Rph3A interacts with GluN2A and PSD-95 forming a complex that regulates
NMDARs stabilization at postsynaptic membranes.
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T
he functional properties of NMDARs (N-methyl-D-
aspartate receptors) depend on their subunit composition.
The identity of NMDAR GluN2-type subunits regulates
biophysical and pharmacological properties of the receptor and
influences receptor assembly, signalling and localization1.
GluN2A-containing NMDARs are rather stable at synapses2,3.
Conversely, GluN2B-containing NMDARs compose a more
mobile pool of NMDARs present at both synaptic and
extrasynaptic sites4,5. In addition, the subunit composition of
synaptic NMDARs changes during development and after
induction of activity-dependent synaptic plasticity6,7. During
development, NMDARs switch from di-heteromes containing
primarily GluN1-GluN2B to NMDARs enriched in GluN2A and
composed of GluN1-GluN2A-GluN2B subunit6,8, this switch
being under the control of epigenetic processes9.
It is believed that protein–protein interactions determine the
specific synaptic retention of NMDARs with different GluN2-
type subunits. In the last decade, PSD-95, Discs Large and Zona
Occludens 1 (PDZ)-mediated interactions with PSD-MAGUK
members, for example, PSD-95, have been clearly demonstrated
to favour surface expression and stabilization of both GluN2A
and GluN2B within the postsynaptic membrane10,11. A working
model proposes that binding of GluN2 subunits to distinct PSD-
MAGUKs plays a key role in NMDAR localization to either
synaptic or extrasynaptic sites1,7. Current data support this
scenario for GluN2B as the disruption of the GluN2B PDZ-
binding domain results in a loss of synaptic GluN2B12,13. The
mechanisms responsible for synaptic retention of NMDARs
containing the GluN2A subunit are much less clear. Mice lacking
the C-terminal domain of GluN2A show a reduced synaptic
GluN2A expression14,15 and peptides affecting GluN2A/PSD-
MAGUKs interaction reduce synaptic retention of NMDARs3,16.
Notably, additional domains in the GluN2A C-terminus acting to
stabilize NMDARs at synaptic sites have been proposed17–19.
Based on these considerations, we performed a yeast two-hybrid
(Y2H) screening using the intracellular C-terminal sequence of
GluN2A and we identified Rabphilin 3A (Rph3A) as a potential
partner.
Rph3A is known as a vesicle-associated presynaptic protein,
first identified as a binding partner of Rab3A20, involved in the
regulation of synaptic vesicle traffic21. Rph3A directly binds to
other proteins including the MAGUK protein CASK22, SNAP-25
(ref. 23) and MyoVa24, localized in the pre- or post-synaptic
compartment. Mice that lack Rph3A are viable and fertile without
obvious physiological impairments25. Notably, synaptic
properties impaired in Rab3A knock-out mice were found
unaffected in Rph3A knock-out mice25. Thus, even if a large
amount of information on the presynaptic pool of Rph3A is
available, there is no consensus on the precise role of Rph3A in
presynaptic terminals. And, no information is available on a
possible postsynaptic localization and function of Rph3A.
Here we demonstrate the presence of Rph3A in the
postsynaptic density (PSD) at excitatory synapses and indicate a
novel function for Rph3A in the stabilization of GluN2A-
containing NMDARs at synapses through the formation of a
ternary complex with GluN2A and PSD-95.
Results
Rph3A is present at dendritic spines of excitatory synapses.
A Y2H screening, performed using the GluN2A C-terminal
domain (amino acids (aa) 839–1,461, thus lacking the
PDZ-binding sequence) as bait, identified Rph3A as a novel
GluN2A-binding protein (see Methods for details). Because
Rph3A has been extensively described as a presynaptic protein21,
we first verified whether Rph3A was also present in the
postsynaptic compartment where GluN2A resides. Fluorescent
immunocytochemistry of primary hippocampal neurons showed
that Rph3A co-localizes with PSD-95 and GluN2A
along dendrites as shown in double (Fig. 1a,b) and triple
immunostaining experiments (Supplementary Fig. 1a).
Interestingly, Rph3A co-localization with GluN2A was detected
only in PSD-95-positive postsynaptic clusters. In addition,
Rph3A/PSD-95 co-localization was observed along MAP2-
positive dendrites (Supplementary Fig. 1b). Similarly, RFP-
Rph3A and eGFP-GluN2A expressed in hippocampal neurons
showed a high degree of co-localization at PSD-95-positive
clusters (Fig. 1c). As expected, Rph3A was also found to
co-localize with the presynaptic interacting protein Rab3A20
(Supplementary Fig. 1c) as well as with the pre-synaptic marker
Bassoon (Supplementary Fig. 1d). Using a biochemical
fractionation approach to isolate purified excitatory PSDs from
rat hippocampus, we found the presence of Rph3A in all
subcellular fractions. Rph3A was enriched in synaptosomal
plasma membranes and PSD2 fractions (Fig. 1d) similar to
GluN2A and PSD-95, which are known as main PSD proteins.
As internal controls, synaptophysin and Rab3A, two strictly
presynaptic proteins, were present in several subcellular
compartments analysed but not in PSD1 and PSD2 purified
fractions (Fig. 1d). Rab8, a small GTPase that is specifically
involved in the regulation of secretory/recycling vesicles, shows a
widespread distribution in all synaptic compartments (Fig. 1d). In
agreement with biochemical data, electron microscopic analysis
showed the presence of Rph3A not only in the presynaptic
bouton but also at the lateral domain of the PSD (Fig. 1e) as well
as at multiple locations within dendritic spines and along
dendritic shafts (Fig. 1f). Overall, these results indicate that
Rph3A is present both at presynaptic and postsynaptic sites.
Rph3A interacts with GluN2A and with PSD-95. Several
experimental approaches were used to substantiate the Y2H
data and to confirm the interaction between Rph3A and GluN2A.
Rph3A/GluN2A interaction was detected in co-immunoprecipi-
tation (co-IP) experiments from rat hippocampal P2 crude
membrane fractions (Fig. 1g). Anti-GluN2A immunoprecipitated
samples from P2 fractions were analysed in western blotting
(WB) with Rph3A, GluN2A, PSD-95 and with the nuclear protein
Meox2 as a control. We found a specific interaction of GluN2A
with PSD-95 and Rph3A (Fig. 1g). Interestingly, both GluN2A
and Rph3A also interacted with PSD-95 (Fig. 1g). These inter-
actions are specific, as no signal for GluN2A, PSD-95 or Rph3A
was obtained by using the irrelevant anti-Meox2 antibody or in
the absence of the antibody in the co-IP assay (Fig. 1g).
Co-clustering assay in heterologous COS7 cells and pull-down
experiments were used to identify GluN2A, Rph3A and PSD-95
domains involved in the binding. As previously described26, when
transfected in the absence of GluN1 subunit, eGFP-GluN2A
or eGFP-GluN2B subunits displayed a clustered perinuclear
distribution (Fig. 2a, left panels). Co-transfection of RFP-Rph3A
with eGFP-GluN2A caused a redistribution of eGFP-GluN2A
throughout the cell (Fig. 2a, right panels). Conversely, no effect
on eGFP-GluN2B clustered distribution was observed when co-
transfected with RFP-Rph3A (Fig. 2a, right panels). In addition,
quantification of eGFP-GluN2A co-clustering with RFP-Rph3A
showed a high co-localization value when compared with eGFP-
GluN2B/RFP-Rph3A-transfected cells (Fig. 2b, ***P¼ 0.0003,
unpaired Student’s t-test). Co-transfection of RFP-Rph3A with a
mutant plasmid of GluN2A with a stop codon inserted at the aa
1,049 position fused with enhanced Green Fluorescent Protein
(eGFP) (eGFP-GluN2A(1,049); Fig. 2a) revealed a significant
decrease in the co-localization of GluN2A and Rph3A (Fig. 2b,
***P¼ 0.0006, unpaired Student’s t-test), thus indicating that the
distal GluN2A(1,049–1,464) C-terminal domain is needed for the
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interaction with Rph3A. Glutathione S-transferase (GST) pull-
down assay of Rph3A with fusion proteins of GluN2A C-tails of
various lengths identified the region comprised between aa 1,349
and aa 1,389 as responsible for the interaction with Rph3A
(Fig. 2c). Notably, no sequence homology was found between the
GluN2A(1,349–1,389) sequence and C-tail domains of all other
NMDAR and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptor (AMPAR) subunits, further confirming the
specificity of Rph3A/GluN2A interaction.
Rph3A is an extrinsic membrane protein20,27, able to bind,
through both its C2 domains (C2A (384–488 aa) and C2B
(542–645 aa)), IP3 in a Ca2þ -dependent manner. The calcium-
bound C2 domains mediate interactions with phospholipid
bilayers. Notably, IP3 and Ca2þ binding to the C2A domain
mutually enhance each other. In particular, it has already been
described, through both computational and experimental data,
that the presence of Ca2þ ions induces a conformational
rearrangement of a specific Rph3A loop (namely, CBL3), which
is involved in IP3 binding28,29. Even if no crystallographic
structure is available for rat Rph3A as a whole, its above-
described domains have been separately solved. For this reason,
we propose (see Fig. 2d for details) a relative arrangement of the
two crystallized Rph3A C2 domains (PDB ID: 4NP9 for C2A and
2CM5 for C2B)29 based on the crystallographic structure of the
C2 domains (A and B) of rat synaptotagmin-3 (PDB ID:
1DQV)30. Each Rph3A C2 domain binds two Ca2þ ions and
one IP3 molecule. In agreement with these observations, Ca2þ or
IP3 alone did not modify the affinity of Rph3A for GluN2A C-tail
in a pull-down assay (Fig. 2e,f and Supplementary Fig. 2a;
***Po0.001, one-way analysis of variance (ANOVA) followed by
Tukey post-hoc test). Conversely, co-incubation of samples with
Ca2þ and IP3 induce a dramatic increase of Rph3A binding to
GluN2A (Fig. 2e,f), confirming that both Ca2þ and IP3 are
necessary for an efficient molecular recognition mechanism.
Rat Rph3A contains three main domains (see Fig. 2i for
details): the N-terminal Rab-binding domain (residues
40–157)31–33 and two C-terminal C2-like domains (see
above)27,31,33. It also contains a FYVE-type zinc finger (residues
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Figure 1 | Subcellular distribution of Rph3A and interaction with GluN2A and PSD-95. (a) Fluorescence immunocytochemistry of Rph3A (green) and
PSD-95 (red) in DIV15 primary hippocampal neurons. On last panel (merge), co-localization points are shown in white. Scale bar, 10mm. (b) Fluorescence
immunocytochemistry of GluN2A (green) and Rph3A (red) in DIV15 primary hippocampal neurons. On last panel (merge), co-localization points are shown
in white. Scale bar, 10 mm. (c) Fluorescence immunocytochemistry of eGFP-GluN2A (green), RFP-Rph3A (red) and endogenous PSD-95 (blue) in DIV15
primary hippocampal neurons transfected with eGFP-GluN2A and RFP-Rph3A (DIV9). Scale bar, 10 mm. (d) Subcellular expression of GluN2A, PSD-95,
Synaptophysin (Syn), Rph3A, Rab3A and Rab8 in rat hippocampus. H, homogenate; S1/2, supernatant 1/2; P1/2, pellet 1/2; SPM, synaptosomal plasma
membrane; PSD1/2, postsynaptic density fraction 1/2. (e,f) Immunolabelling of Rph3A in dendritic spines of pyramidal cells in the CA1 stratum radiatum of
the hippocampus. Electron microscopy images show that Rph3A is found lateral to the PSD (white arrowheads) and at different positions in dendritic
spines (white arrowheads). b, bouton, s, spine. (g) Co-immunoprecipitation experiments on rat hippocampal P2 fractions using polyclonal GluN2A,
monoclonal PSD-95 and irrelevant monoclonal Meox2 antibodies show that Rph3A is associated with both GluN2A and PSD-95.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10181 ARTICLE
NATURE COMMUNICATIONS | 6:10181 | DOI: 10.1038/ncomms10181 | www.nature.com/naturecommunications 3
88–145), which targets Rph3A to cell membranes through
the highly specific interaction with the membrane lipid
phosphatidylinositol-3-phosphate. RFP-Rph3A-truncated mutants
were prepared and co-transfected with eGFP-GluN2A in COS-7
cells in order to identify the Rph3A domain responsible for the
interaction with GluN2A. Deletion of C2A and C2B domain of
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Figure 2 | Rph3A interacts with GluN2A. (a) Confocal imaging of COS7 cells transfected with eGFP-GluN2A (green), eGFP-GluN2B (green) or
RFP-Rph3A (red) and cells co-transfected with either eGFP-GluN2A, eGFP-GluN2B and RFP-Rph3A or eGFP-GluN2A(1,049) (green) and RFP-Rph3A.
Scale bars, 10mm. (b) Bar graph representing the percentage of co-localization between eGFP-GluN2A and RFP-Rph3A, eGFP-GluN2B and RFP-Rph3A,
eGFP-GluN2A(1,049) and RFP-Rph3A. Data are presented as mean±s.e.m., n¼ 5–9, ***Po0.001, unpaired Student’s t-test. (c) GST pull-down assay of
Rph3A using C-terminal GluN2A GST fusion protein with different sizes on rat brain extracts. 1, GluN2A (1,049–1,464); 2, GluN2A (1,349–1,461); 3,
GluN2A (1,244–1,389). (d) Tridimensional model for the topological arrangement of the C2 domains of Rph3A (C2A in cyan and C2B in orange), modelled
on the C2 domains of rat synaptotagmin-3. Each domain can bind both IP3 and 2 calcium ions; however, in the selected crystallographic structures,
IP3 (stick rendering and CPK colouring) was solved only with the C2A and calcium (red spheres) with the C2B domain. The topological arrangement of the
Rab-binding domain with respect to the C2 domains cannot be accurately modelled. (e,f) GSTpull-down assay of Rph3A using C-terminal GluN2A(1,049–
1,464) GST fusion protein in the presence or absence of calcium (20mM) and IP3 (1mM). The bar graph represents the binding of Rph3A to the fusion
protein expressed as percentage of control (in absence of both calcium and IP3). Data are presented as mean±s.e.m., n¼6, ***Po0.001; one-way ANOVA
followed by Tukey post-hoc test. (g) Confocal imaging of COS7 cells co-transfected with eGFP-GluN2A and RFP-Rph3A(380) (upper panels), eGFP-GluN2A
and RFP-Rph3A(179) (middle panels) or eGFP-GluN2A(1,049) and RFP-Rph3A(179) (lower panels). Scale bars, 10mm. (h) Bar graph representing the
percentage of co-localization between GluN2A and RFP-Rph3A constructs. Data are presented as mean±s.e.m., n¼ 10, ***Po0.001; one-way ANOVA
followed by Tukey post-hoc test, GluN2A(1,049)/Rph3A(179) versus GluN2A/Rph3A, GluN2A(1,049)/Rph3A(179) versus GluN2A/Rph3A(380),
GluN2A(1,049)/Rph3A(179) versus GluN2A/Rph3A(179). (i) Representative schematic of the different mouse Rph3A mutant constructs used.
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Rph3A as in Rph3A(380) construct did not interfere with
GluN2A/Rph3A clustering (Fig. 2g–i). Similarly, Rph3A(179)
construct bearing a stop codon at aa 179 still interacted with
GluN2A as demonstrated by co-localization assay thus indicating
that the N-terminal Rab-binding domain is responsible for
the binding with GluN2A (Fig. 2g,h). As expected, GFP-
GluN2A(1,049) failed to interact with RFP-Rph3A(179)
(Fig. 2g,h, ***Po0.001; one-way ANOVA followed by Tukey
post-hoc test).
Rph3A contains at its C-terminus a sequence (HVSSD) that
resembles a putative PDZ-binding motif and previous studies
indicated that Rph3A interacts with the presynaptic MAGUK
protein CASK22. GST pull-down assays using GST fusion
proteins of the PDZ1–2 and PDZ3 domains of PSD-95 revealed
that Rph3A can bind PDZ1–2 and PDZ3 domains of PSD-95,
with a higher affinity for PDZ3 (Fig. 3a). To clarify the interaction
of the C-terminus of rat Rph3A with the PDZ3 domain of rat
PSD-95, molecular modelling tasks were carried out. A
crystallographic structure of PSD-95 complexed with a
peptide containing a PDZ-binding sequence was available34.
PDZ-binding sequences usually consist of a signature motif
([FYST]-X-[FVA]), occurring at the very C-terminus of the target
proteins. As the C-terminus of Rph3A is characterized by the
HVSSD sequence, and does not exactly match the PDZ-binding
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Figure 3 | Rph3A interacts with PSD-95. (a) GST pull-down assay of Rph3A using PSD-95 PDZ1–2 or PSD-95 PDZ3 GST fusion proteins on rat brain
extracts. Upper panel: WB analysis performed by using Rph3A antibody. Lower panel: Ponceau staining showing the amount of proteins loaded in each lane.
(b) Left panel: complex between the PDZ3 domain of the rat PSD-95 (in orange) and the CRIPT protein C-terminus (in purple); right panel: complex
between the PDZ 3 domain of the rat PSD-95 (in orange) and the Rph3A C-terminus (in green). Proteins are rendered as ribbons, peptides both as ribbons
and sticks (with CPK colouring). The beta-sheet augmentation, typical of the PDZ domain molecular recognition mechanism, can be appreciated in both
complexes. Binding free energies are reported for each complex. (c) Confocal imaging of COS7 cells co-transfected with PSD-95 (green) and RFP-Rph3A
(red) in the presence or absence of TAT-Rph3A-9c or TAT-Rph3A(VSSD), or PSD-95 and RFP-Rph3A(673) (red). Scale bars, 10mm. (d) Bar graph
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PSD-95 and RFP-Rph3A(673) (n¼ 5–10; unpaired Student’s t test). (e) Confocal imaging of COS7 cells co-transfected with PSD-95 (blue), RFP-Rph3A or
RFP-Rph3A(673) (red) in the presence or absence of GFP-GluN2A (green). Scale bar, 10mm. (f) The bar graph represents the percentage of co-localization
between PSD-95 and RFP-Rph3A constructs (n¼8; one-way ANOVA followed by Tukey post-hoc test). All data are presented as mean±s.e.m., *Po0.05,
**Po0.01, ***Po0.001.
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signature, we computed the binding free energies of the
Rph3A::PSD-95 PDZ3 complex and compared its value with
that from PSD-95 PDZ3 complexed with its cognate ligands, that
is, the C-terminus of the CRIPT protein. The primary structure of
the CRIPT peptide, co-crystallized with PSD-95, was mutated
in silico into HVSSD. The structures of the two complexes,
one between PSD-95 PDZ3 and the peptide from CRIPT,
and the second one between PSD-95 PDZ3 and the Rph3A
C-terminus were then optimized and the binding free energies
were measured. As shown in Fig. 3b, despite its incomplete
compliance with the signature motif of the PDZ-binding
sequence, the affinity of rat Rph3A C-terminus for PSD-95
PDZ3 ( 9.05 kcalmol 1) is highly comparable with the affinity
of a conventional PDZ-binding peptide (from CRIPT) for the
same PSD-95 PDZ 3 domain ( 9.18 kcalmol 1).
In agreement with the co-precipitation (Fig. 1g), pull-down
(Fig. 3a) and molecular modelling studies (Fig. 3b), RFP-Rph3A
displayed a high degree of co-localization with PSD-95 in co-
transfected COS7 cells (Fig. 3c,d). We designed a cell-permeable
TAT peptide containing the last 9 aa of Rph3A C-tail
(TAT-Rph3A-9c) to compete with Rph3A for the binding to
PSD-95. The TAT-Rph3A(VSSD) peptide, lacking the
PDZ-interaction domain (VSSD), was used as a control
(Fig. 3c,d). TAT-Rph3A-9c significantly reduced the degree of
PSD-95/RFP-Rph3A co-localization when compared with cells
treated with the control peptide (Fig. 3c,d; ***P¼ 0.0006;
unpaired Student’s t-test). Further, this co-localization
was markedly decreased when co-transfecting PSD-95 with
RFP-Rph3A(673), a mutant lacking the last 9 aa of Rph3A C-tail
containing the PDZ-binding motif (Fig. 3c,d; **P¼ 0.0014;
unpaired Student’s t-test), confirming the importance of this
domain for the binding to PSD-95.
Notably, co-transfection of GluN2A was sufficient to induce a
significant increase in PSD-95 co-localization degree also with
RFP-Rph3A(673) (Fig. 3e,f; ***Po0.001; one-way ANOVA
followed by Tukey post-hoc test). Interestingly, in the presence
of GluN2A, PSD-95/Rph3A co-localization was significantly
higher compared with PSD-95/Rph3A(673) thus suggesting a
more efficient formation of the GluN2A/PSD-95/Rph3A ternary
complex (Fig. 3e,f; *Po0.05, ***Po0.001; one-way ANOVA
followed by Tukey post-hoc test).
Rph3A stabilizes synaptic GluN2A by blocking endocytosis.
The results described above indicate the presence of a
GluN2A/Rph3A/PSD-95 ternary complex in the postsynaptic
compartment. To understand the role of Rph3A interaction with
GluN2A and PSD-95, we first silenced Rph3A expression
in hippocampal neurons by means of a specific short hairpin
RNA (shRNA; tGFP-shRph3A). tGFP-shRph3A validation
was performed in COS7 cells transfected with RFP-Rph3A
(Supplementary Fig. 2b) as previously reported35.
To isolate the postsynaptic effect of shRph3A, only transfected
neurons very distant from one another, with no contact, were
considered for quantitative analysis. The synaptic localization of
GluN2A (DIV15; GluN2A/Shank co-localization) was decreased
in primary hippocampal neurons transfected with tGFP-shRph3A
(at DIV9) when compared with neurons transfected with
tGFP-shScramble (Fig. 4a,b; **P¼ 0.0011; unpaired Student’s
t-test). No difference was found in the synaptic localization of
GluN2B (Fig. 4a,b; P¼ 0.9951; unpaired Student’s t-test).
To confirm these results and to investigate the role of the
GluN2A/Rph3A/PSD-95 complex at the postsynaptic site, we
used cell-permeable TAT peptides (CPPs) able to interfere with
these protein–protein interactions in neurons. First, we char-
acterized a TAT peptide containing the GluN2A(1,349–1,389)
domain responsible for GluN2A interaction with Rph3A (see
Fig. 2c for details; TAT-2A-40); a scramble sequence was used as
control peptide (TAT-Scr). Administration of TAT-2A-40
(10 mM, 30min) to DIV14 primary hippocampal neurons led to
a significant decrease of GluN2A/Rph3A interaction compared
with TAT-Scr peptide in co-IP assays (Fig. 4c,d, *Po0.05;
unpaired Student’s t-test). Notably, disruption of GluN2A/Rph3A
complex by TAT-2A-40 peptide led also to a concomitant
decrease of GluN2A/PSD-95 interaction (Fig. 4c,e, *Po0.05;
unpaired Student’s t-test), thus further indicating the presence of
a GluN2A/PSD-95/Rph3A ternary complex. As a control, we
verified that TAT-2A-40 did not induce any alteration of
GluN2A, GluN2B, PSD-95 and Rph3A protein levels as evaluated
by WB analysis in neuronal homogenates (Supplementary
Fig. 3a,b).
We observed a significant reduction in the degree of
co-localization between GluN2A and the post-synaptic marker
Shank in neurons treated with TAT-2A-40 compared with those
treated with TAT-Scr (Fig. 4f,g; **P¼ 0.0012; unpaired Student’s
t-test), indicating a decreased enrichment of GluN2A at synapses.
This effect was specific for GluN2A, as TAT-2A-40 had no effect
on GluN2B/Shank co-localization (Supplementary Fig. 3c,d;
P¼ 0.6568; unpaired Student’s t-test). Furthermore, the relative
expression of GluN2A at the membrane surface was significantly
reduced in DIV15 primary hippocampal neurons exposed to
TAT-2A-40 compared with TAT-Scr (Fig. 4h,i; ***Po0.0001;
unpaired Student’s t-test), whereas no effect was observed on the
surface expression of GluN2B (Supplementary Fig. 3e,g;
P¼ 0.1683; unpaired Student’s t-test) or of the GluA1 subunit
of AMPARs (Supplementary Fig. 3f,h; P¼ 0.4062; unpaired
Student’s t-test). Similar results were obtained by quantifying the
GluN2A surface expression within PSD-95 postsynaptic clusters
showing that this reduction is independent of any possible
alteration of PSD-95-positive dendritic spines (Fig. 4j,k;
***Po0.0001; unpaired Student’s t-test).
We further investigated GluN2A surface levels over-time by
performing time-lapse imaging of SEP-GluN2A and SEP-GluN2B
constructs at glutamatergic synapses. A significant reduction in
the signal for SEP-GluN2A, but not for SEP-GluN2B, was
detected at synapses starting 10min after TAT-2A-40 treatment
(Fig. 5a,b, t5: P¼ 0.2363; t10: **P¼ 0.0023; t15: ***P¼ 0.0003;
unpaired Student’s t-test). No difference in dendritic spine size
between the two groups was observed within this time period
(Fig. 5a). No effect of TAT-2A-40 was observed on SEP-GluN2B
fluorescence (Fig. 5c,d). To evaluate whether these effects were
correlated with an increase of GluN2A endocytosis, we repeated
live-imaging experiments in the presence of the dynamin
inhibitor dynasore35. Pre-treatment with dynasore (80 mM)
completely abolished the observed reduction in SEP-GluN2A
signal after TAT2A-40 treatment (Fig. 5e,f). These results
highlight a selective role of Rph3A in the synaptic retention of
GluN2A, and suggest that disruption of the GluN2A/Rph3A
complex promotes GluN2A internalization.
PSD-95/Rph3A interaction is required for GluN2A retention.
We used TAT-Rph3A-9c peptide (see Fig. 3c,d for details)
to understand the role of Rph3A/PSD-95 interaction in the
formation of GluN2A/Rph3A/PSD-95 ternary complex and,
consequently, in the regulation of GluN2A surface level at
synapses. Rph3A co-IP with both GluN2A and PSD-95 in
forebrain membrane fractions was reduced in mice treated
with the TAT-Rph3A-9c peptide 1 h before killing (3mol g 1
intraperitoneal (i.p.); Fig. 6a,b; ***Po0.001 GluN2A/Rph3A,
**Po0.01 PSD-95/Rph3A; unpaired Student’s t-test), thus
suggesting that Rph3A/PSD-95 binding is needed for the
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stabilization of the GluN2A/PSD-95/Rph3A ternary complex.
Accordingly, similar to what was described above for TAT-2A-40,
treatment with TAT-Rph3A-9c led to a significant decrease of
GluN2A levels at synaptic sites in primary hippocampal neurons,
as indicated by the reduction of GluN2A co-localization with the
postsynaptic marker Shank (Fig. 6c,d; **P¼ 0.0069; unpaired
Student’s t-test). TAT-Rph3A-9c also reduced GluN2A surface
staining (Supplementary Fig. 3i,j; *P¼ 0.0130; unpaired Student’s
t-test) and GluN2A surface expression in PSD-95-positive post-
synaptic clusters (Supplementary Fig. 3k,l; ***P¼ 0.005; unpaired
Student’s t-test). Overall, these results indicate that Rph3A/
PSD-95 interaction has a role in the surface stabilization of
GluN2A at synaptic sites similar to Rph3A/GluN2A interaction.
GluN2A/Rph3A/PSD95 complex modulates NMDA currents.
Disruption of Rph3A/GluN2A/PSD-95 ternary complex
decreases the levels of GluN2A at synapses. We directly tested
whether the amplitude of synaptic NMDAR-currents was affected
by performing patch-clamp recordings of pharmacologically
isolated excitatory postsynaptic currents of NMDAR (NMDAR-
EPSCs) in CA1 neurons from hippocampal organotypic slices
(DIV15). We directly included a cell impermeable 2A-40 peptide
(lacking the TAT sequence) into the patch-pipette intracellular
solution enabling postsynaptic targeting of the peptide in a single
cell. A scramble (Scr) peptide (also lacking TAT sequence) was
used as a control. In the presence of the 2A-40 peptide (1 mM),
the amplitude of NMDAR-EPSCs markedly decreased during
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30min of recording as compared with control conditions
(Fig. 7a–c; *Po0.05 2A-40 versus Scr, *Po0.05 2A-40 versus
control; Mann–Whitney test), with no effect on NMDAR-EPSC
decay time (Fig. 7d; 2A-40 versus Scr). This effect was specific to
NMDAR-EPSCs as no change was observed in the amplitude of
AMPAR-EPSCs (Fig. 7e,f). In these experiments, we normalized
the amplitude of the synaptic currents (both NMDAR and
AMPAR mediated) with the average amplitude of the first 3min
of the experiment (see Methods for details). Therefore, disrupting
Rph3A/GluN2A interaction selectively affects the amplitude of
NMDAR-EPSCs, without modulating the kinetics of the synaptic
response, consistent with a decrease of synaptic NMDARs.
To further confirm these observations, we tested the effect of
knocking down Rph3A on glutamatergic synaptic transmission
(Fig. 7g–l). We performed single-cell electroporation of CA1
pyramidal cells in organotypic hippocampal slices with either
tGFP-shScramble or tGFP-shRph3A. Three to five days after
transfection, we recorded the NMDA/AMPA ratio and found that
the ratio was significantly reduced in neurons in which Rph3A
has been knocked down (Fig. 7g, *P¼ 0.0274; Mann–Whitney
test). This result could be interpreted as either a decrease of
NMDAR-mediated currents or an increase of AMPAR-mediated
currents or both. To directly address this, we recorded
pharmacologically isolated NMDAR-EPSCs from a transfected
neuron and a neighbouring non-transfected neuron in pairs
(Fig. 7h). Knock down of Rph3A significantly reduced the
amplitude of synaptic NMDAR-mediated responses compared
with control (Fig. 7i, *P¼ 0.0370; Mann–Whitney test). The
decay time of NMDAR-EPSCs did not vary between the two
conditions, suggesting that the composition of synaptic NMDARs
did not change (Fig. 7i). On the other hand, the amplitude of
pharmacologically isolated AMPAR-EPSCs did not differ between
cells transfected with shRph3A and non-transfected cells (Fig. 7j).
Importantly, no significant difference in the amplitude and decay
time of NMDAR-EPSCs or AMPAR-EPSCs was observed when
cells were transfected with the tGFP-shScramble (Fig. 7k,l).
Overall, these data confirm that the loss of Rph3A reduces the
levels of synaptic NMDARs at hippocampal excitatory synapses.
GluN2A/Rph3A/PSD95 complex modulates spine density. The
role of GluN2 subunits in dendritic spine remodelling has not
been fully investigated8,36,37. We evaluated the role of the
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postsynaptic Rph3A/GluN2A/PSD-95 complex on dendritic
spine morphology by acute treatment (1 h) of primary
hippocampal neurons with TAT-2A-40 or TAT-Rph3A-9c
(and corresponding control peptides) and by knock-down of
Rph3A with tGFP-shRph3A. All experimental approaches
led to a significant reduction in dendritic spine density
compared with control conditions (Fig. 8a,b; *P¼ 0.0165,
TAT-2A-40 versus TAT-Scr; **P¼ 0.0019, TAT-Rph3A-9c
versus TAT-Rph3A(VSSD); **P¼ 0.0053, tGFP-shRph3A
versus tGFP-shScramble; unpaired Student’s t-test). Accordingly,
we also observed a reduction in PSD-95-positive clusters density in
neurons (DIV15) transfected with tGFP-shRph3A compared with
tGFP-shScramble controls (Supplementary Fig. 4a,b, **Po0.01;
unpaired Student’s t-test). We also found that Rph3A silencing in
primary hippocampal cultures induced a mild but not significant
(P¼ 0.055; unpaired Student’s t-test) decrease in PSD-95
expression in total neuronal lysates (DIV15; Supplementary
Fig. 4c,d). For a more detailed morphological analysis, the
dendritic spine length, head and neck width were measured and
then, spines were categorized according to their shape
(mushroom, stubby, thin and filopodia) using a highly validated
classification method38. No statistically significant difference in
spine type was observed following in vitro treatment with CPPs
and Rph3A shRNA (Supplementary Fig. 4e–g). In addition, the
above-described treatments did not modify the percentage of
spine versus filopodia-like protrusions (Supplementary Fig. 4h–j).
In vivo acute treatment (2 h before sacrifice) of mice with
TAT-2A-40 (3 nmol g 1, i.p.) led to a similar decrease in spine
density in CA1 hippocampal neurons (Fig. 8c, *P¼ 0.0184;
unpaired Student’s t-test) and also induced a significant
modification of spine type, namely a reduction of the percentage
of thin spines (Fig. 8d; **P¼ 0.0037; unpaired Student’s t-test).
Disruption of the Rph3A/GluN2A/PSD-95 complex in vivo.
At birth, the abundance of GluN2A-containing NMDARs is very
low in the hippocampus7, their expression increases during
development, starting from the second post-natal week8. This
accumulation of GluN2A-containing NMDARs is crucial for the
maturation of excitatory synapses7. We observed that Rph3A
expression in the hippocampus increased during development in
parallel to GluN2A (Supplementary Fig. 5a). Because of the role
of the Rph3A/GluN2A interaction in stabilizing GluN2A at
synapses, we tested whether this interaction was important for the
developmental increase of synaptic GluN2A.
We chronically treated rat pups with TAT-2A-40 or its control
TAT-Scr peptide (5 injections every other day, starting at P6 and
ending at P14, 3 nmol g 1 subcutaneous (s.c.)). The animals were
then killed at P15 for molecular, electrophysiological and spine
morphology analyses. Biochemical analysis showed that the
chronic treatment with TAT-2A-40 led to a significant decrease
of GluN2A enrichment in a Triton X-100-insoluble postsynaptic
fraction (TIF; Fig. 9a,b; *P¼ 0.0340 as compared with TAT-Scr;
unpaired Student’s t-test) with no changes in Rph3A, GluN2B
and PSD-95 synaptic levels (Fig. 9a,b).
We next assessed the functional consequences of chronic
disruption of Rph3A/GluN2A interaction on synaptic transmis-
sion in patch clamp recordings from CA1 pyramidal cells in
acute slices. We found no difference in the amplitude and
frequency of spontaneous synaptic events (miniature excitatory
postsynaptic current (mEPSC)), in tetrodotoxin and recorded at
 70mV; Supplementary Fig. 5b–d), or in the paired pulse ratio
(40ms and recorded at  70mV; Supplementary Fig. 5e,f).
These data indicate that chronic disruption of the Rph3A/
GluN2A complex does not affect the amount of synaptic
AMPARs (mEPSC amplitude) and probability of release (mEPSC
frequency and paired pulse ratio), further confirming the
postsynaptic locus of action of the TAT-2A-40 peptide. We then
estimated the changes in synaptic NMDARs by measuring
synaptic NMDA/AMPA ratios knowing that the content of
synaptic AMPAR was not affected following TAT-2A-40
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(d) of the peptides (n¼ 5–9). (e) Sample traces show the effect of intracellular perfusion of the non-permeable 2A-40 or its scramble control peptides on
pharmacologically isolated AMPAR-mediated EPSCs ( 70mV). Traces represent the average of 6–9 responses with a scale of 20 pA over 10ms.
(f) Summary graph illustrating the time course of the effect of 2A-40 or its scramble on the peak amplitude of AMPAR-EPSCs. For comparison, it is also
plotted (open circles) the amplitude of AMPAR-EPSCs in the absence of any peptide in the intracellular solution, n¼6–7. (g) Sample traces and summary
graphs illustrating that transfection of tGFP-shRNA-Rph3A induced a significant reduction in the NMDA/AMPA ratio when compared with cells transfected
with tGFP-shRNA-Scramble (tGFP-shRNA-Scramble: 2.03±0.32; n¼9; tGFP-shRNA-Rph3A: 0.89±0.29, n¼ 8; Mann–Whitney test). (h) Schematic
illustrating paired recordings from neighbouring transfected and non-transfected neurons. (i) Sample traces shown in the inset (not transfected (NT):
n¼ 13; tGFP-shRNA-Rph3A: n¼ 13; Mann–Whitney test). (j) Amplitude of AMPAR-mediates EPSCs at SC-CA1 (recorded at  70mV; NT: n¼ 9;
tGFP-shRNA-Rph3A: n¼ 9). (k) Transfection with tGFP-shRNA-Scramble did not modify the amplitude or decay time of NMDAR-mediated EPSCs at
SC-CA1 synapse (NT: n¼ 12; tGFP-shRNA-Scramble: n¼ 12). (l) Transfection with tGFP-shRNA-Scramble did not reduce the amplitude of
AMPAR-mediated EPSCs at SC-CA1 (NT: n¼ 10; tGFP-shRNA-Scramble: n¼ 10). All data are represented as mean±s.e.m. *Po0.05.
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treatment. AMPAR-EPSCs and NMDAR-EPSCs were recorded
from CA1 pyramidal cells, respectively, at  70 and þ 40mV.
The NMDAR-mediated contribution was measured 50ms after
initiation of the EPSC, a time point at which the contribution
of AMPAR-EPSCs is absent or minimal. Treatment with
TAT-2A-40 induced a significant decrease in the NMDA/AMPA
ratio compared with TAT-Scr treatment (Fig. 9c,d, *P¼ 0.0169;
Mann–Whitney test).
Chronic treatment with TAT-2A-40 induced a significant
decrease in the amount of GluN2A but not GluN2B in synaptic
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fractions (Fig. 9a,b). Decrease in the relative abundance of
GluN2A with respect to GluN2B could result in the slowing
down of the kinetics of NMDAR-EPSCs6. Rather unexpectedly,
the kinetics of pharmacologically isolated NMDAR-EPSCs
(in the presence of NBQX 20 mM and recorded at þ 40mV)
were not different among the various treatments (Fig. 9e,f).
To confirm this result, we tested the effect of TCN-201 (10 mM),
a selective blocker of GluN2A-containing NMDARs39, on
pharmacologically isolated NMDAR-EPSCs. We found that
amplitude and kinetics of NMDAR-EPSCs were similarly
inhibited by this drug (Fig. 9g–i; amplitude: *P¼ 0.0313; decay
time: *P¼ 0.0313; Wilcoxon test).
Moreover, chronic treatment of young rats with TAT-2A-40
induced a decrease in spine density of CA1 hippocampal neurons
(Fig. 9j; **P¼ 0.0055; unpaired Student’s t-test), as following
acute treatments (see Fig. 8 for details), without any significant
difference in the proportion of different spine types
(Supplementary Fig. 5g). In agreement with the effect on spine
density, we found a decrease in PSD-95 expression in total
homogenates in the hippocampus of TAT-2A-40 chronically
treated pups compared with their respective TAT-Scr controls
(Supplementary Fig. 5h; **P¼ 0.0026; unpaired Student’s t-test).
Interestingly, two other administration protocols, (i) animals
treated by a single injection of the CPPs at 3 nmol g 1 s.c. at P6
and killed at P15 and (ii) animals treated by a chronic injection of
the CPPs starting at P6 and ending at P14 and killed at P21, led to
a similar decrease of GluN2A-containing NMDARs at synaptic
sites (Supplementary Fig. 5i,j; 1: *P¼ 0.0212, 2: *P¼ 0.023;
unpaired Student’s t-test), thus indicating the persistency of the
molecular effect induced by the disruption of GluN2A/Rph3A
complexes.
Discussion
GluN2A-containing NMDARs are known to be less mobile and
more stable at synapses, as compared with GluN2B-containing
NMDARs1,2,7. However, data on the detailed molecular
mechanisms responsible for the synaptic retention of GluN2A-
containing NMDARs are currently insufficient. Our results
indicate that Rph3A, previously thought to be purely
presynaptic, is required for the stabilization of GluN2A-
containing NMDARs at the postsynaptic membrane in
hippocampal neurons, through the formation of a ternary
GluN2A/Rph3A/PSD-95 complex.
At the presynaptic level20, Rph3A modulates synaptic vesicle
trafficking21. Here we show that Rph3A is not localized
exclusively in presynaptic compartments, but is also present in
the postsynaptic compartment. In particular, electron microscopy
studies indicate the presence of Rph3A at dendritic spines and at
the edge of the excitatory PSD. Notably, our results are in
agreement with several proteomic studies all converging on the
identification of Rph3A as a member of the PSD complex40–43.
In addition, previous studies indicate that Rph3A can interact
with postsynaptic proteins24,44,45, some of these (a-actinin,
Myosin-Va) being able to associate directly to ionotropic
glutamate receptors45,46. Finally, the Rph3A interaction with
PSD-95 described here is consistent with the previously shown
capability of Rph3A to bind CASK, another member of the
MAGUKs family of scaffolding proteins22.
In line with the postsynaptic localization, we show that
Rph3A specifically and directly interacts with GluN2A and with
PSD-95. Our data indicate that Rph3A forms a ternary complex
with GluN2A and PSD-95. Notably, disruption of either
GluN2A/Rph3A or PSD-95/Rph3A interactions leads to a
decreased stability of GluN2A/PSD-95 protein interaction
inducing a rapid decrease of GluN2A-containing NMDARs
inserted in the postsynaptic membrane. Time-lapse confocal
imaging experiments with SEP-GluN2A and measurement of
NMDAR currents concur with a reduction of active NMDARs
at the cell surface within 10–15min after disruption of GluN2A/
Rph3A complex.
Previous reports indicated the presence of stable endocytic
zones on the spine surface near the PSD47–50. Notably, here we
show by electron microscopy studies that Rph3A is localized at
the postsynaptic membranes in close proximity of the PSDs thus
in a strategic position to interfere with receptor endocytosis
through stabilization of the GluN2A/PSD-95 complex. In
agreement with this hypothesis, blocking receptor endocytosis
with the dynamin-inhibitor dynasore35 fully prevents GluN2A
reduction at the cell surface induced by GluN2A/Rph3A complex
disruption. Hence, Rph3A stabilizes GluN2A in the synaptic
membrane and prevents endocytosis likely by strengthening
synaptic GluN2A/PSD-95 interaction.
It is well-known that levels and expression patterns of the
GluN2 subunits change during the first two postnatal weeks.
In particular, GluN2A expression increases from the second
postnatal week to become widely expressed and abundant
throughout the brain8,51. Notably, several studies have
demonstrated that GluN1/GluN2A/GluN2B tri-heteromers
account for at least two-thirds of the total NMDARs in the
adult hippocampus, thus indicating that NMDARs clustering,
synaptic targeting and function at hippocampal synapses are
mainly determined by these tri-heteromeric receptors8,51,52. In
agreement with this idea, we show that a peptide perturbing
Rph3A interaction with GluN2A induces a selective decrease in
the overall amplitude of NMDAR-EPSCs, without modulating
the kinetics of the synaptic response, suggesting that there
are fewer GluN1/GluN2A/GluN2B receptors available for
synaptic activation. Interestingly, both Rph3A shRNA and
GluN2A/Rph3A interfering peptide in hippocampal organotypic
slices (DIV15) and chronic in vivo systemic administration
of the peptide from P6 to P14 rats led to the decrease in
NMDAR-EPSCs.
GluN1 GluN2A GluN2B PSD-95
PDZ1/2
PDZ3
Rph3A Endocytic
vesicle
Figure 10 | Schematic of GluN2A/Rph3A/PSD-95 ternary complex at the
PSD. Rph3A is involved in a ternary complex with GluN2A and PSD-95 to
help stabilize GluN2A-containing NMDARs at the synaptic membrane.
Rph3A localized at the lateral domain of the PSD interacts with the
cytoplasmic C-terminal tail of GluN2A and the PDZ3 domain of PSD-95,
whereas GluN2A can bind to PDZ1 or PDZ2 of PSD-95. Disruption of one of
these interactions is enough to reduce the amount of GluN2A-containing
NMDARs at synaptic membranes affecting the overall amplitude of
NMDARs response and spine density in the hippocampus.
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GluN2A/Rph3A interfering peptides and Rph3A silencing also
caused a significant decrease in dendritic spine density with no
modification of size and overall morphology. A possible
correlation between GluN2A-containing NMDARs and dendritic
spine morphology has been previously proposed. In particular, in
agreement with our results, IQGAP1-dependent impairment of
surface expression of GluN2A-containing NMDARs in hippo-
campal neurons led to a significant reduction of spine density37.
Interestingly, no significant alterations in dendritic spines
number were observed in experimental conditions of more
direct and dramatic reduction of GluN2A levels8,36. This suggests
that a fine modulation of GluN2A surface synaptic localization
but not a more general subunit knock-down could cause changes
in synaptic morphology.
Several studies have proposed that abnormal GluN2-type
subunits trafficking, resulting in the modification of the NMDAR
subunit composition at synapses, has a major role in the
pathogenesis of several brain disorders1,53,54. Moreover, recent
observations clearly indicate that alterations in PSD-MAGUK
protein interaction with GluN2 subunits are common events in
several neurodegenerative disorders10. Interestingly, specific
reductions in Rph3A immunoreactivity in neurodegenerative
disorders, such as Alzheimer’s disease55, a-synucleinopathy56 and
Huntington’s disease57 were observed. Accordingly, Rph3A with
its specific role in modulating synaptic GluN2A-containing
NMDARs could represent an innovative target to rescue an
altered NMDAR subunit composition in CNS disorders.
Altogether, here we report that Rph3A takes part in
GluN2A/PSD-95 complexes playing a crucial role in synaptic
retention of GluN2A-containing NMDARs (Fig. 10).
Methods
Animals. C57/BL6 mice of 6 weeks, Sprague–Dawley rats of 6 weeks, E18 embryos
from Sprague–Dawley rats for primary hippocampal neuron cultures and P6-P21
Sprague–Dawley rat pups were used. All the experiments were approved by the
OHSU Institutional Animal Care and Use Committee and by the Italian Health
Ministry (#295/2012-A). Likewise, all animals were used according to the
guidelines of the University of Bordeaux/CNRS Animal Care and Use Committee
and the requirements of the United Kingdom Animals (Scientific Procedures)
Act 1986.
Y2H screening. Y2H was conducted according to the manufacture’s procedure
guidelines using the Mate & Plate Library—Mouse Brain (normalized; cat
#630488, TakaraBio/Clontech Europe, France). Briefly, the GluN2A(839–1461)
C-tail (bait) was cloned in the pGBKT7 plasmid and transformed in the AH109
haploid yeast strain (MATa). This was mated overnight with the Mouse Brain
normalized library (prays) cloned in pGADT7 transformed in Y187 haploid yeast
strain (MATa). Yeast were plated after 24 h on selective plate, allowing only the
growth of diploid where a protein interaction between the bait and pray protein
occurred (absence of Leucine, Adenine, Tryptophan and Histidine). Then the
diploids were tested by a colorimetric assay (a-gal) to avoid the presence of false
positive. Plasmids (twenty-one positive clones) were extracted from the yeast and
sequenced. Five genes were identified following sequencing, one of those being
Rph3A.
Antibodies. The following primary antibodies were used: rabbit anti-N-term
GluN2A (480031, Invitrogen; dilution 1:100 ICC), rabbit anti-GluN2A (M264,
Sigma-Aldrich; dilution 1:1,000 WB), mouse anti-N-term GluN2B (75–101,
Neuromab; dilution 1:100 ICC, 1:1,000 WB), anti-PSD-95 (75–028; Neuromab;
dilution 1:250 ICC, 1:1,000 WB) and anti-Pan-shank (75–089, Neuromab; dilution
1:200), rabbit anti-N-term GluA1 (MAB2263, Millipore; Billenca, MA; dilution
1:100 ICC), rabbit anti-Rph3A (NB100–92221, Novus biological; dilution 1:100
ICC), mouse anti-Rph3A (RM3701, ECM biosciences; dilution 1:100 ICC, 1:1,000
WB), rabbit anti-Rab8 (D22D8, Cell Signaling; dilution 1:1,000 WB), mouse
anti-Meox2 (ab117551, Abcam; dilution 1:1,000 WB), mouse anti-Tubulin (T9026,
Sigma-Aldrich; dilution 1:5,000 WB). The following secondary antibodies were
used: goat anti-mouse-HRP (172–1,011) and goat anti-rabbit-HRP (172–1,019,
Bio-Rad), goat anti-mouse-Alexa488 (A-11029), goat anti-mouse-Alexa555
(A-21422), goat anti-mouse-Alexa633 (A-21052), goat anti-rabbit-Alexa488
(A-11034) and goat anti-rabbit-Alexa555 (A-21429; Life Technologies). For the
original WB, please see Supplementary Fig. 6.
Plasmids. RFP-Rph3A plasmid was a kind gift from Professor Mitsunori Fukuda
(University of Tokyo, Meguro, Tokyo, Japan). This plasmid was used to perform
point mutation inserting a stop codon for the codon corresponding to aa 673, 380
or 179. PSD-95 fusion proteins plasmids were provided by Professor Yutaka Hata
(Tokyo Medical and Dental University, Japan). eGFP-GluN2A was provided
by Professor Richard Huganir (Johns Hopkins University School of Medicine,
Baltimore, MD, USA). This plasmid was used to perform point mutation inserting
a stop codon for the codon corresponding to aa 1,049. eGFP was provided by
Dr Maria Passafaro (CNR, Milan, Italy). SEP-GluN2A and SEP-GluN2B were
provided by Professor Roberto Malinow through Addgene as plasmid #23997 and
plasmid #23998, respectively58.
Cell-permeable peptides. Each CPP was manufactured by Bachem (Bubendorf,
Switzerland) according to our designed sequences as follows. TAT-Rph3A-9c:
YGRKKRRQRRR-QNENHVSSD; TAT-Rph3A(VSSD): YGRKKRRQRRR-
QNENH; TAT-2A-40: YGRKKRRQRRR-EDSKRSKSLLPDHASDNPFLHTYQDD
QRLVIGRCDSDPYKH; TAT-Scr: YGRKKRRQRRR-LDPHSNPLYCPDLYSERFD
VSKDHRLDKTKSDHAQDRASIG. Lyophilized CPPs were resuspended in sterile
deionized water to a stock concentration of 1mM and stored at  20 C. In vitro
treatments were performed with a 1–10 mM concentrations of CPPs, in vivo
treatments were performed by injecting CPPs at 3 nmol g 1.
Cell cultures and transfections. COS7 cells were grown on 100mm dishes and
maintained in DMEM containing Glutamax (DMEMþGlutamax, GIBCO)
supplemented with 10% fetal bovine serum and penicillin–streptomycin (GIBCO).
Cells were allowed to grow till confluence before passaging every 3–4 days using
trypsin. The day before transfection, COS-7 cells were placed in a 12 wells
multiwell (for imaging), then cells were transfected with 250–500 ng of plasmid
DNA (RFP-Rph3A; RFP-Rph3A(673); eGFP-GluN2A; eGFP-GluN2A(1,049);
PSD-95) using the lipofectamine LTX method (invitrogen). After 36 h, COS-7 cells
were fixed for immunostaining/imaging. Hippocampal neuronal primary cultures
were prepared from embryonic day 18–19 (E18-E19) rat hippocampi59. Neurons
were transfected at DIV9 using calcium-phosphate co-precipitation method with
2–4 mg of plasmid DNA for: RFP-Rph3A; eGFP-GluN2A; eGFP; shRph3A-tGFP or
shScramble-tGFP, (Thermoscientific). Neurons were treated at DIV15, fixed and
then immunostained.
Fluorescent immunocytochemistry. Cells were fixed with 4% Paraformaldehyde
(PFA)-4% sucrose in PBS solution at 4 C and washed several times with PBS. Cells
were either blocked with 5% BSA in PBS for 30min at room temperature and then
labelled with primary antibodies for surface labelling for 1 h at room temperature
or permeabilized with 0.1% Triton X-100 in PBS for 15min at room temperature
and then blocked with 5% BSA in PBS for 30min at room temperature. Cells were
then labelled with antibodies for intracellular epitopes for 1 h at room temperature
or overnight at 4 C. Cells were washed and then incubated with secondary
antibodies for 1 h at room temperature. Cells were then washed in PBS and
mounted on glass slides with Fluoromount mounting medium (Sigma Aldrich)
or permeabilized for total labelling.
Pre-embedding immunocytochemistry. Three Sprague–Dawley male rats
(B6-week-old) of B150 g were used. After terminal anaesthesia was induced by
brief inhalation of isoflurane (0.05% in air), followed by an intramuscular injection
of ketamine (100mg kg 1) and xylazine (10mg kg 1), rats were intracardially
perfused with 4% PFA and 0.1% glutaraldehyde in PBS (0.1M, pH 7.2), and brain
sections (100 mm) were cut on a Leica VT1000S vibratome (Leica Micro-
systems)19,60. The sections were immunolabelled with rabbit anti-Rph3a polyclonal
antibody (1:100; ab68857, Abcam), followed by a biotinylated secondary antibody,
ABC Elite Kit (Vector Laboratories), and the peroxidase reaction was revealed by
ImmPACT VIP substrate Kit (Vector Laboratories). Then the sections were
osmicated, dehydrated and flat embedded in Durcupan resin (Sigma-Aldrich).
Ultrathin sections (70–90 nm) were countercoloured with uranyl acetate and lead
citrate. Control experiments, in which the primary antibody was omitted, resulted
in no immunoreactivity. The sections were visualized with a Philips CM100
transmission electron microscope (FEI) at 100 kV. The images were captured with
an AMT XR40 4 megapixel side mounted CCD camera at a magnification between
 7,900 and  92,000.
Computational procedures. All the computational procedures were carried out
through the Molecular Operating Environment (MOE) version 2014.0901 from the
Chemical Computing Group. The Amber99 forcefield61 with the Generalized Born
implicit solvation method62 was used for all the computational tasks.
The crystallographic structure of the PDZ3 domain of rat PSD-95
co-crystallized with a C-terminal peptide derived from the CRIPT protein
(PDB ID: 1BE9)34 was downloaded and submitted to the Structure Preparation
procedure. The binding free energy between PSD-95 and the CRIPT peptide
was computed through the MOE LigX procedures, useful to minimize the
crystallographic structure and to estimate the binding affinity through the
forcefield-based GBVI/WSA dG scoring function, which estimates the free
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energy of interaction. The complex between the PSD-95 PDZ3 domain and
the C-terminus of Rph3A was obtained by mutating the CRIPT peptide into
HVSSD primary structure with the Protein Design module. The binding free
energy was computed with the MOE LigX as above.
Subcellular fractionations. TIF, a fraction highly enriched in PSD proteins but
absent of presynaptic markers63, was isolated from adult rat hippocampus. To this,
samples were homogenized at 4 C in an ice-cold buffer containing 0.32M Sucrose,
1mM HEPES, 1mM NaF, 0.1mM phenylmethylsulfonyl fluoride (PMSF), 1mM
MgCl in the presence of protease inhibitors (Complete, GE Healthcare) and
phosphatase inhibitors (PhosSTOP, Roche Diagnostics GmbH), using a glass-
Teflon homogenizer. Homogenates were then centrifuged at 1,000g for 5min at
4 C, to remove nuclear contamination and white matter. The supernatant was
collected and centrifuged at 13,000g for 15min at 4 C. The resulting pellet
(P2 crude membrane fraction) was resuspended in hypotonic buffer (1mM HEPES
with Complete). Resuspended P2 were then centrifuged at 100,000g for 1 h at 4 C.
Triton X-100 extraction of the resulting pellet was carried out at 4 C for 20min in
an extraction buffer (1% Triton X-100, 75mM KCl and Complete). After
extraction, the samples were centrifuged at 100,000g for 1 h at 4 C and the TIFs
obtained were resuspended in 20mM HEPES with Complete. PSDs were isolated
from rat hippocampus64. Rats (15 animals) were killed, hippocampi were dissected
within 2min and pooled. All hippocampi dissected in 42min were discarded.
Homogenization was carried out by 10 strokes in a glass-Teflon homogenizer
(700 r.p.m.) in 4ml g 1 of cold 0.32M sucrose containing 1mM HEPES, 1mM
MgCl2, 1mM NaHCO2 and 0.1mM PMSF (pH 7.4). The homogenized tissue was
centrifuged at 1,000g for 10min. The resulting supernatant was centrifuged at
13,000g for 15min to obtain a fraction containing mitochondria and synaptosomes.
The pellet was resuspended in 2.4ml g 1 of 0.32M sucrose containing 1mM
HEPES, 1mM NaHCO3 and 0.1mM PMSF, overlaid on a sucrose gradient
(0.85–1.0–1.2M), and centrifuged at 82,500g for 2 h. The fraction between 1.0 and
1.2M sucrose was removed, diluted with an equal volume of 1% Triton X-100 in
0.32M sucrose containing 1mM HEPES, 15min. This solution was spun down at
82,500g for 45min. The pellet (Triton insoluble postsynaptic fraction, PSD1) was
resuspended, layered on a sucrose gradient (1.0–1.5–2.1M), and centrifuged at
100,000g at 4 C for 2 h. The fraction between 1.5 and 2.1M was removed and
diluted with an equal volume of 1% Triton X-100 and 150mM KCl. PSD2 were
finally collected by centrifugation at 100,000g at 4 C for 45min and stored at
 80 C until processing. All purifications were performed in the presence of
complete sets of protease and phosphatase inhibitors (Roche Diagnostics). Protein
content of the samples was quantified by using Bio-Rad protein assay. After
measuring protein concentration, all samples were standardized at 1 mgml 1
concentration and the same protein amount loaded in each lane. For the original
WB, please see Supplementary Fig. 6.
Co-IP assay. A measure of 50mg of proteins from rat hippocampus or mice
forebrain P2 fractions were incubated for 1 h at 4 C in RIA buffer containing
200mM NaCl, 10mM EDTA, 10mM Na2HPO4, 0.5% NP-40, 0.1% SDS and
protein A/G-agarose beads as pre-cleaning procedure. The beads were then let to
sediment at the bottom of the tube and the supernatant was collected. Primary
antibodies were added to the supernatant before leaving to incubate overnight at
4 C on a wheel. Protein A/G-agarose beads were added and incubation was
continued for 2 h, at room temperature on a wheel. Beads were collected by gravity
and washed three times with RIA buffer before adding sample buffer for
SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and the mixture was boiled
for 10min. Beads were pelleted by centrifugation, all supernatants were applied
onto 7–12% SDS–PAGE gels. For the original WB, please see Supplementary Fig. 6.
Pull-down assay. GST fusion proteins were expressed in Escherichia coli and
purified on glutathione agarose beads (Sigma Aldrich)26. A measure of 250 mg of
brain homogenate proteins were incubated with 20 ml of GST alone proteins to a
final volume of 1ml in Tris-Buffered Saline (TBS, 10mM Tris and 150mM NaCl)
for 1 h on the rotator at room temperature. Samples were then centrifuged at
3,000 r.p.m. for 90 s and the supernatants were incubated for 2 h with 40 ml of GST
fusion proteins of the C-terminal domains of GluN2A, PDZ1–2 or PZ3 domains of
PSD-95 or GST alone. After incubation, beads were washed four times with TBS
and 0.1% Triton X-100. For the Ca2þ /IP3 experiments, 175mg of hippocampal
homogenate proteins were incubated with 10 ml of GST alone proteins to a final
volume of 500 ml of TBS for 1 h on the rotator at room temperature. Samples were
then centrifuged at 3,000 r.p.m. for 90 s and the supernatants were incubated for 2 h
at room temperature with 25 ml of GST-GluN2A(1,049–1,464) or GST alone fusion
proteins along with 20mM Ca2þ , 1mM IP3 or 20mM Ca2þ and 1mM IP3. After
incubation, beads were washed four times with TBS and 0.1% Triton X-100. Bound
proteins were resolved by SDS–PAGE and subjected to immunoblot analysis. For
the original WB, please see Supplementary Fig. 6.
Slice electrophysiology. Organotypic hippocampal slice cultures were prepared
from P5–P7 rat pups65, according to guidelines of the University of Bordeaux/
CNRS Animal Care and Use Committee. Three to four days after plating, the
medium was replaced and then changed every 2–3 days. Electrophysiological
experiments were performed after 10–16 days in culture. After 7–9 days in vitro,
we performed single-cell electroporation to transfect individual cells with cDNAs
encoding tGFP-shRNA-Scramble or tGFP-shRNA-Rph3A. Plasmids (50 ng/ml 1)
were dissolved in a filtered Kþ -based intracellular solution to fill 6–9MO patch
clamp pipettes. Electroporation was performed in a pre-warmed HEPES-based
artificial cerebrospinal fluid (ACSF) by the delivery of 50–100 square-pulses (600 ms
duration) at 100Hz with an amplitude of  10mV. Electrophysiological recording
were performed 3–5 days after transfection.
For acute slices recordings, sagittal hippocampal slices (330 mm thick) were
obtained from 15-day-old rat killed by cervical dislocation, 24 h after the last i.p.
injection either with TAT-2A-40 or its scramble version (4 animals per condition
were used). Acute slices were prepared using sucrose-based cutting solution and
used until a maximum of 6 h after cutting. Slices were transferred to a recording
chamber in which they were continuously superfused with an oxygenated
extracellular solution (95% O2 and 5% CO2) containing 125mM NaCl, 2.5mM
KCl, 1.25mM NaH2PO4, 26mM NaHCO3, 2.3mM CaCl2, 1.3mM MgCl2 and
25mM glucose.
Whole-cell voltage-clamp recordings (3.5–4.5Mo electrodes) were made from
CA1 pyramidal cells visualized by infrared videomicroscopy. Slices were perfused
with an extracellular solution identical to the one used for slice incubation.
Bicuculline (10 mM) was added to the bath to block GABAA receptors. The
intracellular solution was composed of: 140mM cesium methanesulfonate, 2mM
MgCl2, 4mM NaCl, 5mM phosphocreatine, 2mM Na2ATP, 10mM EGTA,
10mM HEPES, 0.33mM GTP (pH 7.3). Experiments in slice cultures were
performed in the presence of N6-cyclopentyladenosine (50 nM) to reduce
polysynaptic activity. Evoked postsynaptic responses were induced in CA1
pyramidal cells by stimulating Schaffer collaterals in stratum radiatum (0.1Hz)
with a monopolar glass pipette. After obtaining the cell attached configuration, we
waited 5–10min before entering in whole cell while stimulating Schaffer collateral
with an intensity just below the threshold required to elicit an action potential
monitored in cell attached configuration6. After entering whole cell, we waited
1–3min before starting the recording to adjust the stimulation intensity to have
similar staring amplitude (between 100 and 200 pA) of the NMDAR-EPSCs in all
the experimental conditions. AMPAR-mediated EPSCs were recorded at  70mV
in the presence of competitive NMDAR blocker AP5. In experiments shown in
Fig. 7a–f, nonpermeable 2A-40 or its scramble peptides (both at 1 mM) were
delivered postsynaptically through the recording pipette; ‘Control’ refers to
experiments in which the intracellular solution did not contain any peptides.
In experiments in which the peptides were dialysed via the patch pipette, we
normalized the amplitude of the synaptic currents (both NMDA and AMPA
receptor mediated) with the average amplitude of the first 3min of the experiment.
Statistical comparison was done between the average of the synaptic currents of the
first 3min with respect to the amplitude of the between minutes 27th and 30th.
Pharmacologically isolated NMDAR-mediated EPSCs were recorded at
þ 30mV (Fig. 7a–d) and þ 40mV (Figs 7g,i,k and 9). NMDAR-mediated EPSCs
decay time was calculated with a single weighted decay measure (referred in the
text as decay time) and calculated from the area under the peak-normalized current
for 0.7 s after the peak. For AMPA/NMDA, NMDAR-mediated EPSCs were
measured 50ms after the initiation of the EPSC, a time point at which AMPAR-
mediated currents are absent or minimal. Small, hyperpolarizing voltage/current
steps were given before each afferent stimulus allowing on-line monitoring of input
and series resistance. The access resistance waso20MW, and cells were discarded
if it changed by 420%. No series resistance compensation was used. Recordings
were made using an EPC 10 amplifier (HEKA Elektronik) and were filtered at
0.5–1 kHz, digitized at 5 kHz and stored on a personal computer. Analysis was
performed using Neuromatic (www.neuromatic.thinkrandom. com) written
within the Igor Pro 6.0 environment (WaveMetrics). Values are presented as
mean±s.e.m.
Spine morphology. Carbocyanine dye DiI (Invitrogen) was used to label
neurons66. DiI crystals were applied using a thin needle by delicately touching
region of interest on both sides of 2mm coronal sections prepared from previously
cardiacally fixed with 1.5% PFA in 0.1M phosphate buffer (PB). DiI was left to
diffuse for 1 day in the dark at room temperature, then sections were fixed again
with 4% PFA in PB 0.1M for 45min at 4 C. 150mm coronal sections were then
obtained using a vibratome, the first section was discarded. Sections were mounted
on glass slides with Fluoromount mounting medium (Sigma-Aldrich) for confocal
imaging. DiI crystals were also used on primary hippocampal neurons previously
fixed with 1.5% PFA-4% sucrose in 0.1M PB, where they were applied to the
coverslip with a thin needle and let to diffuse for 30min in 0.1M PB and then fixed
with 4% PFA-4% sucrose in PB for 5min at 4 C. After washing, coverslips were
mounted on glass slides with Fluoromount mounting medium (Sigma-Aldrich) for
confocal imaging.
Confocal imaging. Images were taken using an inverted LSM510 confocal
microscope (Zeiss) and analysed using either the AIM 4.2 software (Zeiss) for
co-localization analysis or ImageJ software. SEP-GluN2A/dTom or SEP-GluN2B/
dTom were imaged on an inverted LSM510 confocal microscope (Zeiss) in
B27-supplemented neurobasal medium without phenol red. To test the population
of surface SEP-GluN2A/B (provided by Professor Roberto Malinow through
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10181
14 NATURE COMMUNICATIONS | 6:10181 | DOI: 10.1038/ncomms10181 | www.nature.com/naturecommunications
Addgene as plasmid #23997 and plasmid #23998, respectively)58, we used low
pH-solution adjusted to pH 5.4, which quenched all the fluorescence indicating
that SEP allows the specific visualization of surface receptors3,58. Images were
acquired over a period of 15min (every 5min). Fluorescence intensity was
measured using ImageJ software only at selected regions of interest (ROI; i.e.
spines) and corrected for background noise, DF/F0 was then calculated and plotted.
Data presentation and statistical analysis. Quantification of WB analysis was
performed by means of computer-assisted imaging (ImageJ) after normalization on
Tubulin levels. For the original WB, please see Supplementary Fig. 6. For surface/
total ratio assays, co-localization and morphological analysis, cells were chosen
randomly for quantification from four to eight different coverslips (two to three
independent experiments), images were acquired using the same settings/exposure
times, and at least ten cells for each condition were analysed. Co-localization
analysis was performed using AIM 4.2 software (Zeiss). Surface ratios were
obtained by dividing the background subtracted fluorescence intensities measured
with ImageJ. Morphological analysis was performed with ImageJ software to
measure spine head width.
All the group values are expressed as mean±s.e.m. Comparisons between
groups were performed using the following tests as appropriate: two-tailed
unpaired Student’s t test, Mann–Whitney test, Wilcoxon test or one-way ANOVA
followed by Tukey post-hoc test. Significance levels were defined as *Po0.05,
**Po0.01, ***Po0.001. Statistical analyses were performed using the GraphPad
Prism statistical package (GraphPad software). Sample sizes are similar to those
generally employed in the field for any specific type of experiment presented in the
manuscript. When appropriate, experiments were performed in blind conditions.
No outlining sample exclusion criteria was used.
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